Expects interim data by early 2024 MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics,…
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial…
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety…
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling…
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients…
– Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe…
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1,…
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing Preclinical proof-of-concept data for…
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative…
Company maintains strong cash position of $207.3 million SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022…
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus…
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth…
– Following the recent submission of the IND application for CNTY-101 and pending FDA clearance,…
Advancement across Company’s pipeline towards regulatory and data milestones BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE)…
Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales…
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023…
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission…
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or…